Related Experiment Video
Updated: Jul 5, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Mouse Melanoma Model in Tumor Vaccines and Immunotherapy Research
Mariangela De Robertis1, Urša Lampreht Tratar2,3, Emanuela Signori4
1Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari 'A. Moro', Bari, Italy.
Abstract:
Efficacy of novel cancer immunization protocols could be tested in cell line-derived xenograft tumor models (CDX), which are based on the implantation of human tumor cell lines into mice for the development of different tumors by numerous means, such as subcutaneous implantation and orthotopic, venial, or peritoneal injections. However, the disadvantages of this model are the biological alteration of the derived cells or the inability of the cell lines to accurately reflect the complexity of tumor heterogeneity. Therefore, syngeneic mouse models, which offer a relatively simple grafting technique, preservation of lineage hierarchy, and the ability to generate tumors in as little as 2-8 weeks, are being used to study potential future applications in medical treatment, particularly immunotherapies. Here, we describe a B16.F10 C57Bl/6 mouse melanoma model we selected for therapeutic studies employing IL-2 and IL-12 immunization protocols. Procedure of tumor cells inoculation and melanoma development in mice is described in detail, as first and necessary set-up for successful immunization experiments.
Insights
Syngeneic mouse models, like the B16.F10 melanoma model, are valuable for cancer immunotherapy research. This study details setting up this model for testing novel immunization protocols, such as IL-2 and IL-12.
Area of Science:
- * Oncology
- * Immunology
- * Preclinical Research
Background:
- * Cell line-derived xenograft (CDX) models have limitations in reflecting tumor heterogeneity.
- * Syngeneic mouse models offer advantages like preserved lineage hierarchy and faster tumor development.
- * These models are crucial for advancing cancer immunotherapies.
Purpose of the Study:
- * To describe the establishment of a B16.F10 C57Bl/6 mouse melanoma model.
- * To detail the procedures for tumor cell inoculation and melanoma development in mice.
- * To provide a foundational setup for subsequent cancer immunization experiments.
Main Methods:
- * Selection of the B16.F10 C57Bl/6 mouse melanoma model for therapeutic studies.
- * Detailed description of tumor cell inoculation techniques.
- * Monitoring of melanoma development in mice following inoculation.
Main Results:
- * Successful establishment of the B16.F10 melanoma model in C57Bl/6 mice.
- * The model facilitates the study of tumor growth dynamics.
- * Provides a necessary foundation for evaluating cancer immunization protocols.
Conclusions:
- * The described B16.F10 mouse melanoma model is a suitable platform for preclinical cancer immunotherapy research.
- * Detailed procedural setup is essential for the success of immunization studies.
- * Syngeneic models are advantageous for investigating novel cancer treatments.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:27Tumor Immunotherapy